KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short-term Investments: 2009-2024

Historic Short-term Investments for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $194.9 million.

  • Biomarin Pharmaceutical's Short-term Investments fell 10.69% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year decrease of 10.69%. This contributed to the annual value of $194.9 million for FY2024, which is 38.85% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Short-term Investments of $194.9 million as of FY2024, which was down 38.85% from $318.7 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Short-term Investments peaked at $567.0 million during FY2022, and registered a low of $194.9 million during FY2024.
  • Moreover, its 3-year median value for Short-term Investments was $318.7 million (2023), whereas its average is $360.2 million.
  • In the last 5 years, Biomarin Pharmaceutical's Short-term Investments skyrocketed by 32.91% in 2022 and then crashed by 43.80% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Short-term Investments stood at $416.2 million in 2020, then rose by 2.49% to $426.6 million in 2021, then soared by 32.91% to $567.0 million in 2022, then slumped by 43.80% to $318.7 million in 2023, then slumped by 38.85% to $194.9 million in 2024.